Formula Growth’s Intersect ENT, Inc XENT Stock Holding History

Formula Growth’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-54,100	Closed	-$1.74M	–	160
2019 Q1	$1.74M	Hold	54,100	–	–	0.25%	92
2018 Q4	$1.52M	Hold	54,100	–	–	0.25%	83
2018 Q3	$1.55M	Sell	54,100 -2,500	-4%	-$75.1K	0.18%	106
2018 Q2	$2.12M	Sell	56,600 -2,500	-4%	-$98.1K	0.23%	85
2018 Q1	$2.32M	Hold	59,100	–	–	0.28%	77
2017 Q4	$1.92M	Hold	59,100	–	–	0.25%	80
2017 Q3	$1.84M	Sell	59,100 -30,000	-34%	-$888K	0.29%	82
2017 Q2	$2.49M	Buy	89,100 +10,000	+13%	+$226K	0.43%	62
2017 Q1	$1.36M	Buy	+79,100	New	+$1.11M	0.28%	102
2016 Q4	–	Sell	-62,213	Closed	-$985K	–	153
2016 Q3	$985K	Hold	62,213	–	–	0.22%	120
2016 Q2	$804K	Hold	62,213	–	–	0.2%	134
2016 Q1	$1.18M	Sell	62,213 -2,600	-4%	-$47.1K	0.28%	113
2015 Q4	$1.46M	Buy	+64,813	New	+$1.28M	0.34%	98

Other funds holding XENT

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Formula Growth's XENT Position: Q2 2019 in Review

Formula Growth sold out of Intersect ENT, Inc (XENT) in Q2 2019, closing a stake of 54,100 shares — an estimated $1.74M sold.

Formula Growth first reported a position in XENT in Q4 2015 and held it in 13 quarters. The position peaked at $2.49M in Q2 2017. 112 funds tracked by Wall St. Rank hold XENT as of Q2 2019.

Formula Growth reported no remaining Intersect ENT, Inc position as of Q2 2019 after selling out during the quarter.
Formula Growth sold 54,100 Intersect ENT, Inc shares in Q2 2019, an estimated $1.74M.
Formula Growth first reported a position in Intersect ENT, Inc in Q4 2015 and held it in 13 quarters.
Formula Growth's Intersect ENT, Inc position peaked at $2.49M in Q2 2017.
112 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2019.

Based on Formula Growth's 13F filing for Q2 2019, filed 14 Aug 2019.